Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aernoud T L Fiolet

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Atherosclerosis|September 7, 2021
Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudyMax J M Silvis, Aernoud T L Fiolet, Tjerk S J Opstal, et al.
Atherosclerosis|May 3, 2025
Interleukin-6 modifies Lipoprotein(a) and oxidized phospholipids associated cardiovascular disease risk in a secondary prevention cohortNiekbachsh Mohammadnia, Amber van Broekhoven, Willem A Bax, et al.
European Journal of Preventive Cardiology|October 31, 2024
The Effects of Colchicine on Lipoprotein(a) and Oxidized Phospholipid Associated Cardiovascular Disease RiskNiekbachsh Mohammadnia, Amber van Broekhoven, Willem A Bax, et al.
Journal of Clinical Epidemiology|November 28, 2020
Text-mining in electronic healthcare records can be used as efficient tool for screening and data collection in cardiovascular trials: a multicenter validation studyWouter B van Dijk, Aernoud T L Fiolet, Ewoud Schuit, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|March 15, 2024
Cost-effectiveness of low-dose colchicine in patients with chronic coronary disease in The NetherlandsAernoud T L Fiolet, Willem Keusters, Johan Blokzijl, et al.
European Heart Journal|March 26, 2021
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trialsAernoud T L Fiolet, Tjerk S J Opstal, Arend Mosterd, et al.
International Journal of Cardiology|December 18, 2022
Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trialTjerk S J Opstal, Stefan M Nidorf, Aernoud T L Fiolet, et al.
Annals of Internal Medicine|May 29, 2023
Association of Low-Dose Colchicine With Incidence of Knee and Hip Replacements : Exploratory Analyses From a Randomized, Controlled, Double-Blind TrialMichelle W J Heijman, Aernoud T L Fiolet, Arend Mosterd, et al.
Frontiers in Cardiovascular Medicine|October 23, 2023
Colchicine and diabetes in patients with chronic coronary artery disease: insights from the LoDoCo2 randomized controlled trialNiekbachsh Mohammadnia, Jan Los, Tjerk S J Opstal, et al.
Heart (British Cardiac Society)|May 20, 2025
Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trialAernoud T L Fiolet, Andrew Lin, Jacek Kwiecinski, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Atherosclerosis|September 7, 2021
Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudyMax J M Silvis, Aernoud T L Fiolet, Tjerk S J Opstal, et al.
Atherosclerosis|May 3, 2025
Interleukin-6 modifies Lipoprotein(a) and oxidized phospholipids associated cardiovascular disease risk in a secondary prevention cohortNiekbachsh Mohammadnia, Amber van Broekhoven, Willem A Bax, et al.
European Journal of Preventive Cardiology|October 31, 2024
The Effects of Colchicine on Lipoprotein(a) and Oxidized Phospholipid Associated Cardiovascular Disease RiskNiekbachsh Mohammadnia, Amber van Broekhoven, Willem A Bax, et al.
Journal of Clinical Epidemiology|November 28, 2020
Text-mining in electronic healthcare records can be used as efficient tool for screening and data collection in cardiovascular trials: a multicenter validation studyWouter B van Dijk, Aernoud T L Fiolet, Ewoud Schuit, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|March 15, 2024
Cost-effectiveness of low-dose colchicine in patients with chronic coronary disease in The NetherlandsAernoud T L Fiolet, Willem Keusters, Johan Blokzijl, et al.
European Heart Journal|March 26, 2021
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trialsAernoud T L Fiolet, Tjerk S J Opstal, Arend Mosterd, et al.
International Journal of Cardiology|December 18, 2022
Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trialTjerk S J Opstal, Stefan M Nidorf, Aernoud T L Fiolet, et al.
Annals of Internal Medicine|May 29, 2023
Association of Low-Dose Colchicine With Incidence of Knee and Hip Replacements : Exploratory Analyses From a Randomized, Controlled, Double-Blind TrialMichelle W J Heijman, Aernoud T L Fiolet, Arend Mosterd, et al.
Frontiers in Cardiovascular Medicine|October 23, 2023
Colchicine and diabetes in patients with chronic coronary artery disease: insights from the LoDoCo2 randomized controlled trialNiekbachsh Mohammadnia, Jan Los, Tjerk S J Opstal, et al.
Heart (British Cardiac Society)|May 20, 2025
Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trialAernoud T L Fiolet, Andrew Lin, Jacek Kwiecinski, et al.
Pageof 4